All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
This is a prospective, multicenter, open-label, non-comparative, non-interventional, observational study to assess te safety and effectiveness of Piqray in the real-world setting
Jun 29, 2022
May 12, 2027
18 Years and older (Adult, Older Adult)
There is no treatment allocation. Patients administered Piqray by prescription will be enrolled.
Subjects eligible for this study must meet all of the following criteria:
Postmenopausal women and men who have a confirmed diagnosis of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA mutated, advanced or metastatic breast cancer.
Patients who have progressed on prior endocrine based therapy and are going to start Piqray treatment for the first time in accordance with the locally approved label.
Patients who are willing to provide written informed consent
Subjects eligible for this study must not meet the following criteria:
Patients with contraindication according to prescribing information for Piqray in Korea.
- Severe hypersensitivity to Piqray or to any of its components
Female subjects who are pregnant and nursing (lactating)
Patients who are sexually active but not willing to follow contraceptive precautions during taking Piqray.
Participants who receive or are going to receive any investigational medicine during surveillance period.